What is Valneva?
Founded in 2012 and headquartered in France, Valneva operates within the pharmaceutical and chemical manufacturing sectors, focusing on the development and production of vaccines for infectious diseases. With a global footprint spanning Europe, the company leverages scientific research and commercial production capabilities to tackle public health challenges. Valneva's strategic focus on preventative healthcare solutions positions it as a key player in the global health industry.
How much funding has Valneva raised?
Valneva has raised a total of $749.8M across 5 funding rounds:
Debt
$27.6M
Debt
$100M
Grant
$27.2M
Corporate Investment
$95M
Debt
$500M
Debt (2016): $27.6M with participation from European Investment Bank
Debt (2020): $100M led by Orbimed and Deerfield
Grant (2022): $27.2M, investors not publicly disclosed
Corporate Investment (2022): $95M featuring Pfizer
Debt (2025): $500M, investors not publicly disclosed
Key Investors in Valneva
Pfizer
Pfizer is a biopharmaceutical company that researches, develops, manufactures, and markets medicines and vaccines across multiple therapeutic areas. The company focuses on areas such as oncology, internal medicine, inflammation and immunology, and vaccines to help prevent, treat, and manage disease worldwide.
Deerfield
Deerfield Management is an investment firm focused on advancing healthcare through investment, intelligence, and philanthropy. The firm supports companies across the healthcare ecosystem with flexible funding models and drives innovation using AI, data, and market research.
European Investment Bank
Established in 1958 and headquartered in Luxembourg, European Investment Bank (EIB) is the European Union's nonprofit long-term lending and finance institution.
What's next for Valneva?
The recent enterprise-level funding and strategic investment signal a period of accelerated growth and development for Valneva. This capital is expected to bolster its research and development pipeline, enhance manufacturing capacity, and potentially expand its market reach. The company's trajectory suggests a continued commitment to innovation in vaccine technology, aiming to address unmet medical needs and strengthen global health security.
See full Valneva company page
